In my profession, I see the proliferation of AI in medicine & therapeutics every day. IMO, AI is going to proliferate every aspect of oncological and medical therapeutics....starting with individualized, tailored genome testing and proteonomics. ABSI has funding thru 2028 plus the backing of AMD+Oracle for guaranteed computer power. What interests me about it is that it has a unique moat: it is the only biotech, public or private, that is targeting non-drug affiliated antibody targets. M&A chance is high as interested in AI augmented biotherapeutics continues to grow. IV on OTM long dated calls was cheap so I bought calls while spot price was $3.15.(CryptoCondom)